Singha Aanuja, K T Magesh, Mahalingam Ramya, M Sathya Kumar, R Aravindhan, A Sivachandran
Oral Pathology and Microbiology, SRM Institute of Science and Technology, SRM Kattankulathur Dental College and Hospital, Chennai, IND.
Cureus. 2023 Jun 4;15(6):e39957. doi: 10.7759/cureus.39957. eCollection 2023 Jun.
Oral cancer poses a serious health challenge to the nations worldwide. India, among all the nations reported, has the largest number of oral cancer cases, which accounts for one-third of the entire population of oral cancer globally. As oral cancer is well-known for delayed diagnosis until an advanced stage, poor outcomes, and a lack of specific biomarkers for the disease and high-budget therapeutic alternatives. Stem cell derivative exosomes gained significant attention as therapeutic agents and diagnostic biomarkers in cancer biology. It's a type of extracellular vesicle, which are lipid-bilayer-enclosed vesicles of endosomal origin. They are nanosized membrane vesicles that are capable of self-renewal, unlimited proliferation, and multi-directional differential potential. Thus, they act salient in the occurrence and development of tumors. Exosomal micro-RNAs (miRNAs) are functionally related to the advancement of cancer, metastasis, and the aggressive nature of tumors with high recurrence rates. It has also been highlighted that exosomes have the potential to serve as diagnostic markers. A quick, easy, high-clarity, and confined rehabilitation method is the basic specification for large-scale usage of exosomes. The constitution of the composite transporters of exosomes is easily available by sampling biological fluids (liquid biopsies) from samples such as saliva. A liquid biopsy based on exosomes focuses on their probable usage in cancer patients' diagnosis and the determination of the outcome or course of the disease. This review explores the therapeutic prospect of stem cell-derived exosomes as intending to offer new ideas for clinical management and institute a new era of therapeutic agents for oral cancer.
口腔癌对全球各国构成了严峻的健康挑战。在所有报告的国家中,印度的口腔癌病例数量最多,占全球口腔癌总人口的三分之一。由于口腔癌直到晚期才被诊断出来,预后较差,并且缺乏针对该疾病的特异性生物标志物以及高成本的治疗选择。干细胞衍生的外泌体作为癌症生物学中的治疗剂和诊断生物标志物受到了广泛关注。它是一种细胞外囊泡,是内体来源的脂质双层包裹的囊泡。它们是纳米级的膜囊泡,具有自我更新、无限增殖和多向分化潜能。因此,它们在肿瘤的发生和发展中起着重要作用。外泌体微小RNA(miRNA)在癌症进展、转移以及具有高复发率的肿瘤的侵袭性方面具有功能相关性。也有人强调外泌体有潜力作为诊断标志物。一种快速、简便、清晰度高且受限的修复方法是外泌体大规模应用的基本要求。通过从唾液等样本中采集生物体液(液体活检),很容易获得外泌体复合转运体的组成。基于外泌体的液体活检关注其在癌症患者诊断以及疾病结局或病程确定中的可能用途。本综述探讨了干细胞衍生外泌体的治疗前景,旨在为临床管理提供新思路,并开创口腔癌治疗剂的新时代。